Jennifer J.D. Morrissette, PhD
Associate Professor of Clinical Pathology and Laboratory Medicine
Clinical Director, Center for Personalized Diagnostics
University of Pennsylvania Perelman School of Medicine
Contact InformationDepartment of Pathology and Laboratory Medicine
3020 Market Street, Suite 220
Philadelphia, PA 19104
Office: 215-898-5578
Fax: 215-898-9817
Email: jennifer.morrissette@uphs.upenn.edu
Specialty Division
Precision and Computational Diagnostics
Education
B.S. (Molecular Biology), State University of New York at Buffalo, 1986
Ph.D. (Molecular Genetics), State University of New York at Buffalo, 1992
Specialty Certification
American Board of Medical Genetics, Clinical Molecular Genetic Diagnostics, 2002
American Board of Medical Genetics, Clinical Cytogenetics, 2002
New York State Certificate of Qualification,
Cytogenetics and Molecular Genetic Diagnostics, 2004
Postgraduate Training
Postdoctoral Fellow, Molecular Genetics, Department of Pathology, Harvard Medical School, Boston MA, 1992-1997
Fellow in Genetics, The Children’s Hospital of Philadelphia, Philadelphia, PA, 1998-2002
Awards and Honors
Mark Diamond Initiative Award, Department of Biological Sciences, State University of New York at Buffalo, 1990
NIH Intramural Research Training Award fellowship, 1992-1993
Pathobiology of Cancer: The Edward A. Smuckler Memorial Workshop, Keystone Colorado, American Association of Cancer Research, 1992
American Social Health Association/Burroughs Wellcome Fund Research Fellowship, 1994-1996
American Association of Cancer Research Fellowship, 1996-1997
General Clinical Research Center (GCRC). Children’s Hospital of Philadelphia, Investigator, 2001-2005
Foerderer Fund for Excellence, Molecular and Cytogenetic Analysis of Autism, 2003-2004
Peter C. Nowell Award in Pathology, University of Pennsylvania, 2013
Memberships and Professional Organizations
American Society Human Genetics, 1998 - Present
Philadelphia Genetics Group, 2004 - Present
American College of Medical Genetics, 2005 - Present
American Cytogenetics Conference, 2006 - Present
Association of Molecular Pathology, 2011 - Present
Web Links
Selected Publications
Genetic Inactivation of CD33 in Hematopoietic Stem Cells to Enable CAR T Cell Immunotherapy for Acute Myeloid Leukemia.
Kim MY, Yu KR, Kenderian SS, Ruella M, Chen S, Shin TH, Aljanahi AA, Schreeder D, Klichinsky M, Shestova O, Kozlowski MS, Cummins KD, Shan X, Shestov M, Bagg A, Morrissette JJD, Sekhri P, Lazzarotto CR, Calvo KR, Kuhns DB, Donahue RE, Behbehani GK, Tsai SQ, Dunbar CE, Gill S., Cell 173(6): 1439-1453, 2018, PMID:29856956
Germline duplication of ATG2B and GSKIP genes is not required for the familial myeloid malignancy syndrome associated with the duplication of chromosome 14q32.
Babushok DV, Stanley NL, Morrissette JJD, Lieberman DB, Olson TS, Chou ST, Hexner EO., Leukemia., 2018, PMID:30087419
Epidermal Growth Factor Receptor Extracellular Domain Mutations in Glioblastoma Present Opportunities for Clinical Imaging and Therapeutic Development.
Binder ZA, Thorne AH, Bakas S, Wileyto EP, Bilello M, Akbari H, Rathore S, Ha SM, Zhang L, Ferguson CJ, Dahiya S, Bi WL, Reardon DA, Idbaih A, Felsberg J, Hentschel B, Weller M, Bagley SJ, Morrissette JJD, Nasrallah MP, Ma J, Zanca C, Scott AM, Orellana L, Davatzikos C, Furnari FB, O'Rourke DM., Cancer Cell 34(): , 2018, PMID:29990498
Interim PET/CT Result Is Not Predictive of Survival in Patients With MYC-rearranged Non-Burkitt Aggressive B-cell Lymphoma.
Cherng HJ, Sargent RL, Nasta SD, Svoboda J, Schuster SJ, Mato AR, Schrank-Hacker A, Morrissette JJD, Landsburg DJ., Clin Lymphoma Myeloma Leuk., 2018, PMID:30033208
In vivo evaluation of EGFRvIII mutation in primary glioblastoma patients via complex multiparametric MRI signature.
Akbari H, Bakas S, Pisapia JM, Nasrallah MP, Rozycki M, Martinez-Lage M, Morrissette JJD, Dahmane N, O'Rourke DM, Davatzikos C., Neuro Oncol., 2018, PMID:29617843
ROS1 Rearrangement in a Case of Classic Biphasic Pulmonary Blastoma.
Jenkins TM, Morrissette JJD, Kucharczuk JC, Deshpande CG., Int J Surg Pathol 26(): , 2018, PMID:29295663
JAK2 V617F-positive acute myeloid leukaemia (AML): a comparison between de novo AML and secondary AML transformed from an underlying myeloproliferative neoplasm. A study from the Bone Marrow Pathology Group.
Aynardi J, Manur R, Hess PR, Chekol S, Morrissette JJD, Babushok D, Hexner E, Rogers HJ, Hsi ED, Margolskee E, Orazi A, Hasserjian R, Bagg A., Br J Haematol., 2018, PMID:29767839
Co-targeting BET and MEK as salvage therapy for MAPK and checkpoint inhibitor-resistant melanoma.
Echevarría-Vargas IM, Reyes-Uribe PI, Guterres AN, Yin X, Kossenkov AV, Liu Q, Zhang G, Krepler C, Cheng C, Wei Z, Somasundaram R, Karakousis G, Xu W, Morrissette JJ, Lu Y, Mills GB, Sullivan RJ, Benchun M, Frederick DT, Boland G, Flaherty KT, Weeraratna AT, Herlyn M, Amaravadi R, Schuchter LM, Burd CE, Aplin AE, Xu X, Villanueva J., EMBO Mol Med., 2018, PMID:29650805
Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells.
Fraietta JA, Nobles CL, Sammons MA, Lundh S, Carty SA, Reich TJ, Cogdill AP, Morrissette JJD, DeNizio JE, Reddy S, Hwang Y, Gohil M, Kulikovskaya I, Nazimuddin F, Gupta M, Chen F, Everett JK, Alexander KA, Lin-Shiao E, Gee MH, Liu X, Young RM, Ambrose D, Wang Y, Xu J, Jordan MS, Marcucci KT, Levine BL, Garcia KC, Zhao Y, Kalos M, Porter DL, Kohli RM, Lacey SF, Berger SL, Bushman FD, June CH, Melenhorst JJ., Nature, 2018, PMID:29849141
A KRAS wild type mutational status confers a survival advantage in pancreatic ductal adenocarcinoma.
Windon AL, Loaiza-Bonilla A, Jensen CE, Randall M, Morrissette JJD, Shroff SG., J Gastrointest Oncol. 9(): , 2018, PMID:29564165
